Market Overview

According to fortune business insights, the global inflammatory bowel disease treatment market size was valued at USD 29.57 billion in 2025. The market is projected to grow from USD 31.24 billion in 2026 to USD 41.64 billion by 2034, exhibiting a CAGR of 3.66% during the forecast period. North America dominated the inflammatory bowel disease treatment market with a market share of 41.01% in 2025.

The analysis shows that the market is growing due to the increasing global prevalence of ulcerative colitis and Crohn's disease, driven by lifestyle changes and environmental factors. A growing emphasis on early diagnosis, rising patient awareness, and adequate reimbursement policies in developed nations are increasing the demand for therapeutics like biologics and inhibitors. Although the COVID-19 pandemic temporarily slowed growth, the market has recovered as key players focus on securing regulatory approvals for new and expanded treatment options.

Major Players Profiled in the Market Report:

• AbbVie Inc. (U.S.)
• Takeda Pharmaceutical Company Limited (Tokyo)
• UCB S.A. (Belgium)
• Bausch Health Companies Inc. (Canada)
• Bristol-Myers Squibb Company (U.S.)
• Pfizer Inc. (U.S.)
• CELLTRION INC. (South Korea)
• Johnson & Johnson Services, Inc. (U.S.)

Segments

Increasing Prevalence of Crohn’s Disease to Dominate Segment Growth

Based on disease indication, the market is divided into Crohn's disease and ulcerative colitis. The Crohn’s disease segment holds the largest market share owing to its increasing prevalence and the rising number of patients undergoing treatment for the condition globally.

Rapid Adoption of Biologics to Drive Injectables Segment Expansion

By route of administration, the market is categorized into oral and injectables. The injectables segment is leading the market, driven by the increasing adoption and regulatory approval of biologic drugs, which are a cornerstone for treating moderate to severe IBD and are typically administered via injection.

Rise in Development by Key Players to Drive TNF Inhibitors Segment

Based on drug class, the market is segmented into IL Inhibitors, TNF inhibitors, anti-integrin, JAK Inhibitors, and others. The TNF inhibitors segment holds the largest market share owing to the widespread use of these monoclonal antibodies to induce and maintain remission and the strong focus of key pharmaceutical companies on developing their pipeline of TNF inhibitors.

Favorable Reimbursement Policies to Bolster Hospital Pharmacy Segment